Rifabutin with lopinavir/ritonavir in patients coinfected with tuberculosis and HIV in Burkina Faso

Conditions

HIV/AIDS Tuberculosis

Kouanda S, Ouedraogo HG, Cisse K, Compaoré TR, Sulis G, Diagbouga S, Roggi A, Tarnagda G, Villani P, Sangare L, Simporé J, Regazzi M, Matteelli A.

2020-06-262 citations

10.1186/s12879-020-05169-2

Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis–HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week

Henri Gautier Ouédraogo, Alberto Matteelli, Giorgia Sulis, Tégwindé Rébeca Compaore, Serge Diagbouga et al. (14 authors)

Annals of Clinical Microbiology and Antimicrobials2020-01-224 citations

10.1186/s12941-020-0345-6

Interventions

Rifabutin 150 mg

control group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - HIV-1 infected patient - Patient aged ¿18 years(minimum) and ¿ 60 years (maximum) - Eligible for antiretroviral therapy including Lopinavir/ritonavir regimen (national guideline) - Any CD4+ - New pulmonary tuberculosis (TPM), confirmed or suspected - Eligible for antimycobacterial therapy including rifabutin - Signed informed consent form - For female patients : pregnancy test negative, non lactating, not planning to become pregnant during the follow-up period of the study.

Exclusion criteria

Exclusion criteria: - Patient doubly infected HIV 1 and 2 or HIV2 - ALAT > 5 NV - creatinine> 3 NV - Co-administration of treatment with an absolute contre indication (list to be established)Pregnancy or breastfeeding - Presence of medical conditions or other conditions (allergy, intolerance) that contraindicate the administration of a drug in the studioChoice of the clinician to take antiretroviral therapy other than as provided under the Protocol - People with MDR or XDR tuberculosis strain from - Any medical condition that in the opinion of the investigator poses a risk to the patient

Design outcomes

Primary

Measure	Time frame
Area under the curve of rifabutin and the area under curve of Lopinavir/ritonavir : -Measured after 15 days of combined treatment rifabutin - lopinavir/ritonavir	—

Secondary

Measure	Time frame
The number of subjects with adverse events to the development of combination treatment (both rifabutin that Lopinavir /r) during treatment with rifabutin 150 mg or 300 mg. ;The number of subjects with adverse events to the development of combination treatment (both rifabutin that Lopinavir /r) during treatment with rifabutin 150 mg or 300 mg.	—

Countries

Burkina Faso

Contacts

Public ContactHenri Gautier Ouedraogo

PharmD, MSC, research assistant

gouedraogo@irss.bf+226 50335684

Outcome results

None listed